188 related articles for article (PubMed ID: 27392940)
1. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
Wang W; Erbe AK; Alderson KA; Phillips E; Gallenberger M; Gan J; Campana D; Hank JA; Sondel PM
Cancer Immunol Immunother; 2016 Sep; 65(9):1047-59. PubMed ID: 27392940
[TBL] [Abstract][Full Text] [Related]
2. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
3. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
4. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
[TBL] [Abstract][Full Text] [Related]
5. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
6. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
7. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.
Makanga DR; Jullien M; David G; Legrand N; Willem C; Dubreuil L; Walencik A; Touzeau C; Gastinne T; Tessoulin B; Le Gouill S; Mahé B; Gagne K; Chevallier P; Clemenceau B; Retière C
Oncoimmunology; 2021 Jun; 10(1):1936392. PubMed ID: 34178429
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
9. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
10. NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand.
Pittari G; Liu XR; Selvakumar A; Zhao Z; Merino E; Huse M; Chewning JH; Hsu KC; Dupont B
J Immunol; 2013 May; 190(9):4650-60. PubMed ID: 23554313
[TBL] [Abstract][Full Text] [Related]
11. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
[TBL] [Abstract][Full Text] [Related]
12.
Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
[TBL] [Abstract][Full Text] [Related]
13. KIR specificity and avidity of standard and unusual C1, C2, Bw4, Bw6 and A3/11 amino acid motifs at entire HLA:KIR interface between NK and target cells, the functional and evolutionary classification of HLA class I molecules.
Gwozdowicz S; Nestorowicz K; Graczyk-Pol E; Szlendak U; Rogatko-Koros M; Mika-Witkowska R; Pawliczak D; Zubala M; Malinowska A; Witkowska A; Nowak J
Int J Immunogenet; 2019 Aug; 46(4):217-231. PubMed ID: 31210416
[TBL] [Abstract][Full Text] [Related]
14. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro.
Rose MJ; Brooks AG; Stewart LA; Nguyen TH; Schwarer AP
J Immunol; 2009 Oct; 183(7):4502-8. PubMed ID: 19748981
[TBL] [Abstract][Full Text] [Related]
15. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
16. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
17. Can we make a better match or mismatch with KIR genotyping?
Mehta RS; Rezvani K
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):106-118. PubMed ID: 27913469
[TBL] [Abstract][Full Text] [Related]
18. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
[TBL] [Abstract][Full Text] [Related]
19. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
20. Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.
Goldenson BH; Zhu H; Wang YM; Heragu N; Bernareggi D; Ruiz-Cisneros A; Bahena A; Ask EH; Hoel HJ; Malmberg KJ; Kaufman DS
Front Immunol; 2020; 11():561553. PubMed ID: 33178188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]